NICE rejects BioMarin's Batten disease drug

14 February 2018

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance that does not recommend Brineura (cerliponase alfa) made by US rare disease drug developer BioMarin Pharmaceutical (Nasdaq: BMRN) for children with neuronal ceroid lipofuscinosis type 2 (CLN2) – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.

This preliminary decision, which is now the subject of public consultation until March 5, comes as the company confirmed it is to negotiate with NHS England terms that could allow the drug to be made available while uncertainties in the evidence of its long term benefits are addressed.

Brineura was approved in Europe last June and in in April 2017 in the USA, where BioMarin executives said the drug would have an average net price of $486,000 per patient per year.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK